Lördag 21 December | 17:38:13 Europe / Stockholm

Kalender

Tid*
2025-05-06 N/A Årsstämma
2025-02-12 12:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-07-30 - Split QLIFE 2000:1
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-08 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2023
2023-11-13 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 - Årsstämma
2023-03-24 - Extra Bolagsstämma 2022
2023-02-16 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-08 - Kvartalsrapport 2021-Q3
2021-08-16 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2024-06-07 12:41:18

The exercise period for warrants series TO 4 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue of units in February 2024 (the "Rights Issue") begins today, 7 June 2024.

Terms for warrants series TO 4 in brief:
  • The exercise price is SEK 0.02 per share.
  • The exercise period runs from 7 - 21 June 2024.
  • Each warrant entitles the holder to subscribe for one (1) share. Upon exercise of all 1,048,696,624 outstanding warrants, 1,048,696,624 shares will be issued.
  • If the warrants are fully exercised, the Company will receive approximately MSEK 21.0 before issue costs.
  • Upon full exercise of all warrants, the number of shares in Qlife will increase with 1,048,696,624 to 5,685,729,046 shares, and the share capital will increase with SEK 3,932,612.34 to SEK 21,321,483.9225.
  • The outcome is planned to be announced on June 25, 2024.

In total, Qlife issued 131,087,078 units in the Rights Issue, each unit consisting of twenty-three (23) shares, eight (8) warrants series TO 4 and eight (8) warrants series TO 5. One (1) warrant series TO 4 entitles the holder to subscribe for one (1) new share in the Company during the period 7 - 21 June 2024 at an exercise price of SEK 0.02 per share and one (1) warrant series TO 5 entitles the holder to subscribe for one (1) new share in the Company during the period 21 November - 5 December 2024 at an exercise price of SEK 0.0225 per share.

In the event of full exercise of all warrants of series TO 4, the Company will receive approximately MSEK 21.0 before issue costs. In order for the warrants not to expire and lose their value, they must be actively sold by 18 June 2024 at the latest, or be exercised no later than 21 June 2024.

Note that warrants that have not been actively sold by 18 June 2024 at the latest, or been exercised no later than 21 June 2024, will expire and lose their value.

Exercise of warrants series TO 4
Trustee-registered warrants

If the warrant holder holds warrants in a deposit account, in an investment savings account or endowment insurance (trustee-registered holdings), subscription and payment will take place with the trustee, which will provide further instructions on how to exercise the warrants. The warrant holder should contact their trustee well in advance for further instructions regarding exercise of the warrants.

Directly registered warrants (securities account)

Directly registered warrant holders can order an application form via info@eminova.seor by phone on +46 8-684 211 00. Payment is made in accordance with the instructions in the application form. Both the application form and payment must be submitted to Eminova Fondkommission AB by 15.00 CEST on 24 June 2024 at the latest.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34